Patents by Inventor Lori Friedman

Lori Friedman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marks as modifiers of the p53 pathway and methods of use
    Patent number: 8153384
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 10, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Helen Francis-Lang, Danxi Li, Roel P. Funke, Marcia Belvin, Mario N. Lioubin
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20110223619
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: May 17, 2011
    Publication date: September 15, 2011
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • HPRP4s modifiers of the p53 pathway and methods of use
    Patent number: 7993829
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: August 9, 2011
    Assignee: Exelixis Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Tak Hung, Helen Francis-Lang, Danix Li, Roel P. Funke, Michael Costa
  • GFATS as Modifiers of the P53 Pathway and Methods of Use
    Publication number: 20110159508
    Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: October 7, 2010
    Publication date: June 30, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • C20ORF23 as modifier of the IGFR pathway and methods of use
    Patent number: 7943302
    Abstract: Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: May 17, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR
    Publication number: 20110086837
    Abstract: The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein.
    Type: Application
    Filed: October 11, 2010
    Publication date: April 14, 2011
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Iris T. Chan, Lori Friedman, Klaus P. Hoeflich, John Prescott, Jeffrey Wallin
  • PDEs as modifiers of the IGFR pathways and methods of use
    Patent number: 7888047
    Abstract: Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: February 15, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • Marks as modifiers of the p53 pathway and methods of use
    Publication number: 20100325743
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 10, 2010
    Publication date: December 23, 2010
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • HADHs as Modifiers of the p21 Pathway and Methods of Use
    Publication number: 20100275275
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: August 5, 2009
    Publication date: October 28, 2010
    Applicant: EXELIXIS INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES
    Publication number: 20100233164
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: March 11, 2010
    Publication date: September 16, 2010
    Inventors: Allen J. Ebens, JR., Lori Friedman
  • MAN2As as modifiers of the IGFR pathway and methods of use
    Patent number: 7785805
    Abstract: Human MAN2A genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of MAN2A are provided.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: August 31, 2010
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, HaiGuang Zhang, Timothy S. Heuer
  • SCDs As Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20100159470
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Application
    Filed: February 26, 2010
    Publication date: June 24, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • C20ORF23 as modifier of the IGFR pathway and methods of use
    Publication number: 20090202563
    Abstract: Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.
    Type: Application
    Filed: March 10, 2005
    Publication date: August 13, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • RORS as Modifiers of the p21 Pathway and Methods of Use
    Publication number: 20090149413
    Abstract: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
    Type: Application
    Filed: December 1, 2008
    Publication date: June 11, 2009
    Applicant: EXELIXIS INC.
    Inventors: Helen Francis-Lang, Lori Friedman, Thomas Kidd, Siobhan Roche, Haiguang Zhang
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20090098135
    Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 10, 2008
    Publication date: April 16, 2009
    Inventors: Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Publication number: 20090068186
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Application
    Filed: April 18, 2007
    Publication date: March 12, 2009
    Applicant: Exelixis Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • PDES AS MODIFIERS OF THE IGFR PATHWAYS AND METHODS OF USE
    Publication number: 20090013416
    Abstract: Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided
    Type: Application
    Filed: March 10, 2005
    Publication date: January 8, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • MARKs as Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20080166709
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: January 28, 2007
    Publication date: July 10, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • SCDs As Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20080102070
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Application
    Filed: September 10, 2007
    Publication date: May 1, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory Plowman, Timothy Heuer
  • Itpks as Modifiers of the Igfr Pathway and Methods of Use
    Publication number: 20070292349
    Abstract: Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.
    Type: Application
    Filed: January 27, 2005
    Publication date: December 20, 2007
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette Parks, Kenneth Shaw, Lynn Bjerke, Timothy Heuer